Traverse

Traverse Biotech is a private New York City-based immunotherapy company focused on sourcing and advancing clinically validated technologies from outside the United States. The company develops first-in-class and differentiated immunotherapies through a risk-sharing partnership model with external licensors, leveraging partner technical, manufacturing, and regulatory capabilities to accelerate development. Its disclosed pipeline spans oncology and adjacent disease areas, with a lead T-cell engager program, TB-Bs1, targeting ROR2-positive solid tumors. Traverse positions itself as a capital-efficient translational biotech that advances programs from preclinical development through early clinical proof-of-concept.